NEW YORK ( TheStreet) -- Orexigen Therapeutics (Nasdaq: OREX) hit a new 52-week low Friday as it is currently trading at $1.56, below its previous 52-week low of $1.57 with 432,680 shares traded as of 1:16 p.m. ET. Average volume has been 1.5 million shares over the past 30 days.

Orexigen has a market cap of $76.9 million and is part of the health care sector and drugs industry. Shares are down 80% year to date as of the close of trading on Thursday.

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
  • Practice your OREX trading strategies and win cash in our stock game.

TheStreet Ratings rates Orexigen as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. You can view the full Orexigen Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

If you liked this article you might like

First Witness to Testify in Pharma Bro's Trial Felt 'Betrayed'

These 5 Stocks Under $10 Are Set to Soar Higher

5 Stocks Under $10 Set to Soar

Orexigen Therapeutics (OREX) Stock Plunges on Q4 Miss

8 Stocks Under $10 Making Big Moves Higher